BioMarin’s $270M Inozyme Acquisition Brings Drug That Could Become First for a Rare Disease

Inozyme Pharma’s main asset is in pivotal testing in children who have a rare enzyme deficiency that affects bones and blood vessels. BioMarin Pharmaceutical, already well established in enzyme replacement, said it will use its experience and infrastructure to grow the market for this product, potentially for several indications. The post BioMarin’s $270M Inozyme Acquisition…

Read More

Media Call: What the Reconciliation Bill’s Medicaid and ACA Provisions and Other Policy Changes Could Mean for States and Health Coverage

DATE: May 16, 2025 Earlier this week, the House Energy and Commerce and Ways and Means Committees both proposed a series of Medicaid and ACA changes, including new work and verification requirements, a reduction in the expansion match rate for states that use their own funds to cover undocumented immigrants, a freeze on provider taxes,…More

Read More

Nursing Exodus Continues: 4 in 10 Plan to Leave by 2029

The country’s nursing workforce has seen slight recovery since the pandemic, but burnout and stress continue to fuel high levels of turnover. New research reveals troubling retention trends — with more than 138,000 nurses having left the workforce since 2022 and 40% of nurses planning to leave the profession within five years. The post Nursing…

Read More

Driving Medical Device Security through Cyber Hygiene

The Growing Threat of Cyberattacks in Healthcare Healthcare systems face an unprecedented wave of cyberattacks, from ransomware that locks critical systems to data breaches exposing patients’ private information. The stakes in these attacks extend beyond financial losses; they threaten patient safety and the continuity of care.  Why is healthcare targeted? Valuable Data: Protected Health Information…

Read More

Driving Synthetic Biology Forward Through Adoption of Technology Enabling Rapid DNA and mRNA Synthesis

Breakthroughs in synthetic biology could help accelerate advances in applications from novel infectious disease vaccines, precision immunotherapy for cancer and antibody therapeutics to creation of engineered meat substitutes and sustainable cellular agricultural products. The post Driving Synthetic Biology Forward Through Adoption of Technology Enabling Rapid DNA and mRNA Synthesis appeared first on MedCity News.

Read More